Discover ESMO's new social media dashboard where you will find all your favourite posts and tweets in one place!
#ESMO40 Celebrate with us: watch our anniversary videos, take a virtual stroll through our timeline of 'ESMO firsts' or share your wishes for the future with us…
There are many good reasons to become an ESMO member. Find out why you should join Europe's leading medical oncology society
See the full list of benefits that ESMO members enjoy including access to OncologyPRO, subscription to Annals of Oncology and reduced meeting registration fees
The ESMO membership booth will be at several oncology meetings in 2018. See where we'll be next!
Our network of National Representatives act as ambassadors of ESMO’s mission in their respective country
All the important ESMO dates and deadlines in a single place - don't miss out, update your diaries now!
Keep up to date with news about ESMO guidelines, including the latest CPG publications, updated recommendations, algorithms, pocket guidelines and MCBS grading
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC3) • Prevention and Screening in BRCA Mutation Carriers and Other Breast/Ovarian Hereditary Cancer Syndromes • Primary Breast Cancer
Cancers of Unknown Primary Site
Neuroendocrine Bronchial and Thymic Tumours • Neuroendocrine Gastroenteropancreatic Tumours • Adrenal Cancer • Thyroid Cancer
Rectal Cancer • Biliary cancer • Gastric cancer • Oesophageal cancer • Cancer of the pancreas • Metastatic colorectal cancer • Anal cancer • Early colon cancer • Familial risk colorectal cancer • Hepatocellular carcinoma
Cancer of the Prostate • Bladder Cancer • Renal Cell Carcinoma • Penile Carcinoma • Testicular Seminoma and Non-Seminoma
Cervical cancer • Endometrial cancer • Gestational trophoblastic disease • Newly diagnosed and relapsed epithelial ovarian carcinoma • Non-epithelial ovarian cancer
Waldenstrom's macroglobulinaemia • Chronic myeloid leukaemia • Newly diagnosed and relapsed mantle cell lymphoma • Multiple myeloma • Newly diagnosed and relapsed follicular lymphoma • Extranodal diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma • Acute lymphoblastic leukaemia • Peripheral T-cell lymphomas • Diffuse large B cell lymphoma • Chronic lymphocytic leukaemia • Hairy cell leukaemia • Philadelphia chromosome-negative chronic myeloproliferative neoplasms • Myelodysplastic syndromes • Hodgkin lymphoma • Primary cutaneous lymphomas • Acute myeloblastic leukaemia in adult patients • Gastric marginal zone lymphoma of MALT type
Nasopharyngeal Cancer • Squamous-Cell Carcinoma of the Head and Neck
Prevention and Screening in BRCA Mutation Carriers and Other Breast/Ovarian Hereditary Cancer Syndromes
Early and locally advanced non-small-cell lung cancer • Metastatic non-small-cell lung cancer • Thymic epithelial tumours • Malignant pleural mesothelioma • Small-cell lung cancer
Cutaneous Melanoma
EANO and ESMO guidelines on leptomeningeal metastasis from solid tumours • High-grade malignant glioma
Soft Tissue and Visceral Sarcomas • Gastrointestinal Stromal Tumours • Bone Sarcomas
Management of anaemia and iron deficiency in patients with cancer • Management of infusion reactions to systemic anticancer therapy • Management of toxicities from immunotherapy • Management of febrile neutropaenia • MASCC and ESMO consensus guidelines for the prevention of chemotherapy and radiotherapy-induced nausea and vomiting • Treatment of dyspnoea in advanced cancer patients • Central venous access in oncology • Management of oral and gastrointestinal mucosal injury • Management of refractory symptoms at the end of life and the use of palliative sedation • Advanced care planning in palliative care • Bone health in cancer patients • Cancer, fertility and pregnancy • Management of chemotherapy extravasation • Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy • Management of cancer pain • Management of venous thromboembolism in cancer patients • Diarrhoea in adult cancer patients • Delirium in Adult Cancer Patients
The ESMO-Magnitude of Clinical Benefit Scale – promoting clear and unbiased communication about the benefit of cancer treatments
Download the new version of our App with the latest Pocket Guidelines for professionals and Guides for Patients
To assist those using and/or evaluating the ESMO Guidelines, download the methodology here
The course will take place in Valencia, Spain; 19-24 July 2018
The 4th ESMO Academy will take place: 1-3 September 2018, Oxford, UK
The course will take place in Naples, Italy; 2-7 September 2018
14-15 September 2018, Paris, France
Save the date for ESMO 2018 Congress. 19-23 October 2018, Munich, Germany
10th European Multidisciplinary Congress on Urological Cancers - EMUC 2018: 8-11 November 2018, Amsterdam, The Netherlands
Join us in Singapore for ESMO Asia 2018. 23-25 November 2018
Join us in Geneva, Switzerland, 13-16 December 2018
The ESMO Summit Africa 2019 will take place in Cape Town, South Africa: 15-17 February 2019
TAT 2019 will take place in Paris, France. 25-27 February 2019
ICHNO 2017 will be held in Barcelona, Spain. 14-16 March 2019
Join us in Geneva, Switzerland, 10-13 April 2019
Save the date for ESMO Breast Cancer 2 – 4 May 2019, Berlin, Germany
Save the date for ESMO 2019. 27 September – 1 October 2019, Barcelona, Spain
ESMO 2020 Congress will take place from 18 to 22 September 2020.
The ESMO Advanced Courses aim to address specific therapeutic challenges in patient management in different tumour settings.
Apply now to join one of our Preceptorship courses!
ESMO fosters the advancement of cancer research by supporting clinical trials workshops to inspire young oncologists from different disciplines across the globe to become the next generation of active researchers.
View the complete list of ESMO oncology conferences including partnership meetings
If you're attending an ESMO event make sure you download our Events App for fast access to programmes, floor plans & much more!
Access information and reports from past ESMO events
ESMO World Congress on Gastrointestinal Cancer 2018: 20 - 23 June 2018, Barcelona, Spain
Addressing the daily needs of ESMO young oncologists
Invest in your future and the future of cancer care. Learn more about our Oncology Fellowship Programme.
The latest oncology jobs can be found here, including information on how to post a job
ESMO has developed a number of awards that recognise excellence in the field of oncology. Nominate your candidate for the 2018 ESMO Awards
The 2016 edition of ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology and the 2017 edition of the associated Log Book are now available
Register now for the 2018 ESMO examination – a valuable assessment tool for practicing medical oncologists and for medical oncologists in training
If you’ve already sat the ESMO exam, then take a look at our CME opportunities
Advancing the careers of female oncologists to become the leaders of tomorrow
An inspiring programme for future ESMO leaders
Attend sessions at Congress knowing your child is having fun and in safe hands
An ESMO pre-selected listing of the most recent EU research funding opportunities
Relevant information and tools to guide you through various EU grant application procedures
A selection of funding organisations to assist you in your projects
What`s available in terms of clinical research training and educational events
Clear, relevant information on EU clinical trials and data protection legislation
Useful links to partners and tools for your research projects
General European grant scheme information highlighting the main objectives, available funding and target audiences
Guides for Patients are designed to assist patients, their relatives and caregivers to better understand the nature of different types of cancer and evaluate the best available treatment choices
Video interviews and articles designed to help patients, policy makers and other non-medical professionals better understand the principles of personalised cancer medicine
Now available in Romanian, our Guide for Patients with Advanced Cancer is designed for patients, their family members and oncologists.
The ESMO Designated Centres of Integrated Oncology and Palliative Care accreditation programme recognises cancer centres which provide comprehensive services in supportive and palliative care as part of their routine care.
The ESMO Patient Advocacy Track encourages communication between patients, families, oncologists and healthcare professionals.
Medical oncology is included among the medical specialities covered by the European Commission Directive 2005/36/EC.
ESMO’s political initiatives aim to promote the profession of medical oncology and keep cancer policy high on the European healthcare agenda.
ESMO position statements and recommendations can be downloaded here.
The objective of this ESMO-led study is to provide health authorities with data on the availability of licensed anti-neoplastic medicines
ESMO has endorsed the 'Prague Charter: Relieving suffering' set up by the European Association for Palliative Care (EAPC) & other organisations
ESMO seeks to eradicate cancer at its earliest stages through effective cancer prevention awareness and advocacy campaigns.
Rare Cancers Europe is a multi-stakeholder initiative dedicated to putting rare cancers firmly on the European policy agenda.
Information about the EFPIA Disclosure Code which comes into effect 1 January 2015
News from the ESMO Policy section
Welcome to OncologyPRO, the home of ESMO’s educational and scientific resources, with Guidelines, a comprehensive list of E-Learning modules, Factsheets on biomarkers, slides and webcasts from our educational programme, and more... to support continuing medical education and daily practice!
OncologyPRO offers ESMO members exclusive content such as ESMO’s Congresses webcasts, daily Oncology news, accrual of CME points, free downloads of ESMO’s educational books and a direct access to Annals of Oncology.
The Management, Treatment & Future Perspectives of Cancer of Unknown Primary
ESMO Supported Meeting
21/03/2014
22/03/2014
http://www.cupfoundjo.org/conference
London
United Kingdom
9 Cat. 1
English
Yes, for ESMO Young Oncologists
56% for ESMO Junior members
Yes
Carcinoma of unknown primary site
There are no related objects.
